article thumbnail

This Protein May Protect Against Alzheimer’s, Scientists Say

AuroBlog - Aurous Healthcare Clinical Trials blog

In the search for a treatment for Alzheimer’s disease, researchers have zeroed in on a protein with protective effects. A new study reveals how cholesterol and inflammation in different types of human brain cells interact with a protein called ABCA7, which regulates how molecules pass through cell membranes.

Protein 220
article thumbnail

Flashing Lights And a Clicking Sound Cleared Toxic Proteins in Alzheimer’s Mice

AuroBlog - Aurous Healthcare Clinical Trials blog

Scientists have now demonstrated how stimulating high-frequency brain waves in mice can clear out the amyloid protein clumps associated with Alzheimer’s. Could Alzheimer’s disease one day be treated by flashes of light and clicks of sound?

Protein 176
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Feinstein Institutes researchers discover new protein for sepsis treatment

Pharmaceutical Technology

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein 263
article thumbnail

Kymera’s protein degrader starts Phase II trial in atopic dermatitis

Pharmaceutical Technology

Following the dosing of the first patient in Phase II atopic dermatitis trial, Kymera received a $15m milestone payment from Sanofi.

Protein 130
article thumbnail

Aqilion and Merck partner to develop TAK1 protein inhibitors

Pharmaceutical Technology

Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors. Merck will be responsible for leading the preclinical pharmacology and biology trials.

Protein 147
article thumbnail

Fierce Pharma Asia—Daiichi's leukemia nod; Astellas' protein degrader pact; Takeda's neuroscience setback

Fierce Pharma

Astellas signed another protein degrader deal, this time with PeptiDream. Astellas signed another protein degrader deal. Takeda's enzyme replacement therapy flunked a mid-stage trial in a rare neurological disorder. Daiichi Sankyo's FLT3 inhibitor overcame FDA rejection to win an approval. Plus more.

Protein 92
article thumbnail

Eloxx repackages ELX-02 data in cystic fibrosis as it eyes pivotal trial

Pharmaceutical Technology

Eloxx has revealed its lead candidate ELX-02 improved predicted forced expiratory volume (ppFEV1) in patients with Class 1 cystic fibrosis (CF) in a new analysis of a Phase II trial that missed its efficacy endpoints. The regimen in the trial was a one-week monotherapy period (1.5

Trials 246